Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks

NCT02474316 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT02474316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02474316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks
Lead sponsor
Ruijin Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
August 31, 2014
Completion date
December 31, 2017
Enrollment
366 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b